Welcome to ACTIV-1 IM
The Clinical Trial of Immune Modulators for Treating COVID-19
Welcome to ACTIV-1 IM
The Clinical Trial of Immune Modulators for Treating COVID-19
ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS & VACCINES
COVID-19 Therapeutics Prioritized for Testing in Clinical Trials
COVID-19 Therapeutics Prioritized for Testing in Clinical Trials
COVID-19 Therapeutics Prioritized for Testing in Clinical Trials
ACTIV is a public-private partnership developing research strategies for prioritizing and speeding development of treatments and vaccines for COVID-19. The National Institutes of Health and the Foundation for the NIH (FNIH) are bringing together more than a dozen leading biopharmaceutical companies, the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration and the European Medicines Agency to develop an international strategy for a coordinated research response to the COVID-19 pandemic.
The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership is developing a collaborative framework for prioritizing vaccine and drug candidates, streamlining clinical trials, coordinating regulatory processes and/or leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics.
ACTIV-1 IM
COVID-19 Therapeutics Prioritized for Testing in Clinical Trials
COVID-19 Therapeutics Prioritized for Testing in Clinical Trials
The ACTIV public-private partnership has evaluated hundreds of available therapeutic agents with potential application for COVID-19, and prioritized the most promising candidates. The ACTIV-1 IM clinical trial will test promising immune modulator compounds, a class of drugs that help minimize the deleterious effects of an overactive immune response to SARS-CoV-2 infection.
This Phase 3 trial will enroll hospitalized adults with moderate to severe COVID-19 disease. It will evaluate the safety and efficacy of at least three immune modulators when given as an add-on therapy to remdesivir, an antiviral approved for treatment of COVID-19, and the standard of care in use at local clinics. The different treatments will be assessed with respect to illness severity, recovery speed, mortality and hospital resource utilization.